The role of the pyrin inflammasome in the pathogenesis of MKD was confirmed in PBMCs from HIDS patients, in which pharmacological activation of PKN, leading to the downstream inhibition of the pyrin inflammasome, reduced IL-1β release (72). This evidence concerns the gene IL1B and mevalonic aciduria.